Publications by authors named "K Tsurumi"

Background: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected.

Methods: We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity.

View Article and Find Full Text PDF

Background: This study was conducted to evaluate the real-world safety and efficacy of boron neutron capture therapy (BNCT) with borofalan(B) in Japanese patients with locally advanced or locally recurrent head and neck cancer (LA/LR-HNC).

Methods: This prospective, multicenter observational study was initiated in Japan in May 2020 and enrolled all patients who received borofalan(B) as directed by regulatory authorities. Patient enrollment continued until at least 150 patients were enrolled, and adverse events attributable to drugs, treatment devices, and BNCT were evaluated.

View Article and Find Full Text PDF

Aim: Narratives are important in psychiatric rehabilitation. People with a psychiatric diagnosis find it difficult to recall specific autobiographical memories of events that lasted less than a day. Although personal narratives play a central role in personal recovery, the factors influencing personal and clinical recovery, such as psychiatric symptoms and cognitive function, have not been fully explored.

View Article and Find Full Text PDF
Article Synopsis
  • Durvalumab has been used in patients with unresectable stage III non-small cell lung cancer (NSCLC), but its effectiveness for those with epidermal growth factor receptor (EGFR) mutations is still uncertain.
  • A study analyzed 673 patients who received chemoradiotherapy (CRT), finding 51 with EGFR mutations; those patients showed a higher percentage of females and never-smokers.
  • Both EGFR-positive and negative groups exhibited similar progression-free survival rates post-durvalumab treatment, with pneumonitis being the most common adverse effect, suggesting durvalumab may be a viable option for EGFR-positive patients.
View Article and Find Full Text PDF